Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 216.00M
March 31, 2026 242.94M
December 31, 2025 256.55M
September 30, 2025 238.95M
June 30, 2025 216.62M
March 31, 2025 202.78M
December 31, 2024 193.11M
September 30, 2024 181.01M
June 30, 2024 168.04M
March 31, 2024 155.73M
December 31, 2023 142.72M
September 30, 2023 93.82M
June 30, 2023 79.83M
March 31, 2023 74.55M
December 31, 2022 74.51M
September 30, 2022 72.97M
June 30, 2022 78.89M
March 31, 2022 85.06M
December 31, 2021 92.58M
September 30, 2021 86.69M
June 30, 2021 85.36M
March 31, 2021 83.98M
December 31, 2020 91.42M
September 30, 2020 103.98M
June 30, 2020 22.86M
Date Value
March 31, 2020 30.34M
December 31, 2019 34.40M
September 30, 2019 39.58M
June 30, 2019 24.68M
March 31, 2019 38.35M
December 31, 2018 49.66M
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017 73.80M
September 30, 2017 142.47M
June 30, 2017 147.27M
March 31, 2017 129.04M
December 31, 2016 133.00M
September 30, 2016 123.28M
June 30, 2016 121.60M
March 31, 2016 114.24M
December 31, 2015 107.99M
September 30, 2015 100.52M
June 30, 2015 93.24M
March 31, 2015 86.40M
December 31, 2014 89.33M
September 30, 2014 81.26M
June 30, 2014 74.49M
March 31, 2014 76.24M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. 137.28M
Perspective Therapeutics, Inc. 323.86M
ABVC BioPharma, Inc. 10.29M
Enovis Corp. 1.477B
Edwards Lifesciences Corp. 10.62B

Shareholders Equity (Quarterly) Related Metrics